Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Clyra Medical [Member] Common Stock [Member]	Clyra Medical [Member] Additional Paid-in Capital [Member]	Clyra Medical [Member] Retained Earnings [Member]	Clyra Medical [Member] AOCI Attributable to Parent [Member]	Clyra Medical [Member] Noncontrolling Interest [Member]	Clyra Medical [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Common Stock [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Additional Paid-in Capital [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Retained Earnings [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] AOCI Attributable to Parent [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Noncontrolling Interest [Member]	BioLargo Energy Technologies, Inc (BETI) [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2022													278,462,706
Balance at Dec. 31, 2022													$ 186,000	$ 148,435,000	$ (143,594,000)	$ (149,000)	$ (2,867,000)	$ 2,011,000
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares)													4,201,402
Sale of stock for cash, net of offering costs of $39 (unaudited)													$ 3,000	797,000	0	0	0	800,000
Stock for service (in shares)													930,490
Issuance of common stock for services (unaudited)													$ 1,000	206,000	0	0	0	207,000
Stock option compensation expense (unaudited)													0	195,000	0	0	0	195,000
Clyra Medical stock options issued for services (unaudited)													0	61,000	0	0	0	61,000
Clyra Medical stock issued for services (unaudited)							$ 0	$ 0	$ 0	$ 0	$ 550,000	$ 550,000	0	0	0	0	225,000	225,000
Clyra Medical Preferred Series A dividend (unaudited)													0	0	0	0	(27,000)	(27,000)
Noncontrolling interest allocation (unaudited)													0	467,000	0	0	(467,000)	0
Net loss													0	0	(247,000)	0	(247,000)	(494,000)
Foreign currency translation (unaudited)													$ 0	0	0	(6,000)	0	(6,000)
Balance (in shares) at Mar. 31, 2023													284,122,581
Balance at Mar. 31, 2023													$ 190,000	150,191,000	(143,841,000)	(155,000)	(2,833,000)	3,552,000
Issuance of common stock in exchange for Clyra shares (in shares)													527,983
Warrant issued for interest													$ 0	30,000	0	0	0	30,000
Balance (in shares) at Dec. 31, 2023													292,945,747
Balance at Dec. 31, 2023													$ 196,000	154,023,000	(147,098,000)	(277,000)	(2,642,000)	4,202,000
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares)													2,160,348
Sale of stock for cash, net of offering costs of $39 (unaudited)													$ 1,000	487,000	0	0	0	488,000
Stock for service (in shares)													288,997
Issuance of common stock for services (unaudited)													$ 1,000	82,000	0	0	0	83,000
Warrant exercise (unaudited)													0	75,000	0	0	0	75,000
Stock option compensation expense (unaudited)													0	429,000	0	0	0	429,000
Clyra Medical stock options issued for services (unaudited)													0	59,000	0	0	0	59,000
Clyra Medical stock issued for services (unaudited)													0	52,000	0	0	0	52,000
Clyra Medical common unit offering (unaudited)	$ 0	$ 0	$ 0	$ 0	$ 475,000	$ 475,000	$ 0	$ 0	$ 0	$ 0	$ 50,000	$ 50,000
Clyra Medical Preferred Series A dividend (unaudited)													0	0	0	0	(86,000)	(86,000)
Noncontrolling interest allocation (unaudited)													0	399,000	0	0	(399,000)	0
Net loss													0	0	(410,000)	0	(365,000)	(775,000)
Foreign currency translation (unaudited)													$ 0	0	0	96,000	0	96,000
Balance (in shares) at Mar. 31, 2024													295,801,370
Balance at Mar. 31, 2024													$ 198,000	$ 155,606,000	$ (147,508,000)	$ (181,000)	$ (2,967,000)	$ 5,148,000
Warrant exercise (unaudited) (in shares)													406,278